alt

52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)

September 9-12, 2012, San Francisco

ICAAC 2012: Progression of Anal Neoplasia is Common among Gay Men with HIV

Nearly 40% of HIV positive men with low-grade anal neoplasia may progress to high-grade neoplasia or anal cancer, according to a Spanish study presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in San Francisco. Younger age and shorter duration of HIV infection were risk factors for worsening disease.alt

Read more:

ICAAC 2012: HCV Polymerase Inhibitor Sofosbuvir Appears Safe and Effective for HIV/HCV Coinfected People

HIV/altHCV coinfected people taking the experimental hepatitis C virus (HCV) polymerase inhibitor sofosbuvir (formerly GS-7977) experienced a rapid decline in HCV viral load similar to that seen in HIV negative patients, researchers reported this week at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. Side effects were also similar, and there was no sign of interactions with antiretroviral drugs in this 14-day study

Read more:

ICAAC 2012: Stribild Quad Pill Has Potent Anti-HIV Activity with Fewer Side Effects

An integrated analysis of data from Phase 2 and 3 trials, presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco, showed that the newly approved Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) single-tablet regimen had antiviral efficacy at least as good as comparison regimens, and was associated with fewer adverse events than Atripla or boosted atazanavir (Reyataz).alt

Read more:

ICAAC 2012: New Long-acting HIV Fusion Inhibitor Albuvirtide Looks Promising in Early Studies

A new fusion inhibitor that prevents HIV entry into cells showed potent antiviral activity in early clinical studies and has a long half-life suggesting it may be suitable for once-weekly dosing, Chinese researchers reported yesterday at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. alt

Read more:

ICAAC 2012: Hepatitis B Vaccine Effective Long-term, but Some Lose Protection after 15 Years

Nearly all children who received 3 doses of the Engerix-B hepatitis B vaccine achieved protective immunity, but about 20% fell below the protective antibody threshold by year 15 and could benefit from a booster shot, Canadian researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco. alt

Read more: